The pancreatic signal of GLP‐1 receptor agonists: A biliary phenomenon rather than direct toxicity

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are fundamental in the management of type 2 diabetes mellitus (T2DM) and obesity. While early preclinical data raised concerns regarding direct pancreatic toxicity, contemporary human evidence from 2020 to 2025 has shifted the safety narrative. Meta-analyses of randomized controlled trials (RCTs) demonstrate no statistically significant independent association between GLP-1 RA use and acute pancreatitis (AP) (MH-OR 1.24 [0.94, 1.64]; P = .13).However, real-world data identifies a transient increase in risk during the first 6 months of treatment (HR 1.340; 95% CI, 1.239-1.449; P = .019). We propose that this 'pancreatic signal' is an indirect, biliary-mediated phenomenon driven by rapid weight loss and drug-induced gallbladder dysmotility via cholecystokinin (CCK) inhibition. Rather than restricting the indications of these cardioprotective therapies, clinical focus should pivot towards proactive biliary monitoring during the initial 24 weeks of therapy.